CANBRIDGE-B (01228) intends to issue approximately 19.76% of 749.715 million shares for subscription, raising around 98.618 million Hong Kong dollars. Trading will resume on August 13th.

CANBRIDGE-B (01228) announced that on August 12, 2025 (before the trading session), the company entered into a subscription agreement with subscriber Baiyang Health Industry International Trading Co., Ltd. Under this agreement, the company has conditionally agreed to issue and the subscriber has conditionally agreed to subscribe for 74.9715 million subscription shares at a subscription price of HK$1.34 per subscription share. The subscription price of HK$1.34 per subscription share represents a discount of approximately 19.76% compared to the closing price of HK$1.67 per share on the Stock Exchange of Hong Kong on August 11, 2025 (the last trading day). The total amount of funds raised from the subscription will be HK$100 million, and after deducting related expenses incurred in relation to the subscription, it is estimated that the net amount receivable by the company from the subscription will be approximately HK$98.6618 million. The company intends to use the net proceeds from the subscription for (i) the research and development of commercialized products; (ii) marketing and promotion activities; (iii) repayment of loan financing and borrowings; and (iv) daily operations of the group. At the company's request, trading in the shares has been suspended on the Stock Exchange of Hong Kong from 9:00 am on August 12, 2025, pending the publication of this announcement. The company has applied to the Stock Exchange of Hong Kong for the resumption of trading in the shares from 9:00 am on August 13, 2025.